Do we need to revise the dose of isoniazid for the treatment of tuberculosis in children?

A young boy in a wheelchair holding a teddy bear sits in the foreground of a clinic examination room, while a male doctor in a white coat and a female healthcare worker in dark clothing confer in the background against a pale yellow wall.
Image Credit: Photo by Ortopediatri Çocuk Ortopedi Akademisi on Unsplash (SourceLicense)

About This Article

This is an AI-generated summary of a research paper. The original authors did not write or review this article. See full disclosure ↓

European Respiratory Journal·2026-03-01·View original paper →

Overview

Pediatric tuberculosis remains a significant global health burden, with approximately 1.25 million children aged 0-14 years affected annually and case notification rates substantially lower in this population compared to adults. Diagnostic challenges specific to the pediatric population, including inability to produce sputum samples, paucibacillary disease presentation, and limited radiological access in resource-constrained settings, contribute to delayed diagnosis and treatment initiation. Integration gaps between primary child healthcare and tuberculosis programmatic care further complicate treatment management and outcomes in this age group.

Methods and approach

The abstract presents a contextual framework for pediatric tuberculosis management rather than a primary research methodology. The discussion incorporates evidence-based treatment algorithms developed to standardize care approaches, integrated within the World Health Organization operational handbook for tuberculosis in children. Additionally, a comprehensive clinical standard was developed through a Delphi process to establish consensus-based guidance for healthcare workers managing tuberculosis in pediatric and adolescent populations.

Results

The abstract does not present empirical research results or findings from a study. Rather, it identifies key challenges in pediatric tuberculosis diagnosis and treatment management, including lower case notification rates in children aged under 5 years and mortality of approximately 15 percent among affected children. The abstract emphasizes the availability of evidence-based treatment algorithms and clinical standards designed to support healthcare staff in managing tuberculosis across pediatric age groups.

Implications

Standardized, evidence-based treatment algorithms and clinical standards represent organizational efforts to improve quality of care for children and adolescents with tuberculosis. Enhanced integration between primary child healthcare systems and tuberculosis programmatic care is necessary to facilitate timely treatment initiation and management. Continued development of diagnostic approaches and accessibility improvements in resource-limited settings remain critical needs to address the gap in case notification rates and mortality in this population.

Disclosure

  • Research title: Do we need to revise the dose of isoniazid for the treatment of tuberculosis in children?
  • Authors: Jan-Willem C. Alffenaar, Shashikant Srivastava, Rosella Centis, Giovanni Battista Migliori
  • Publication date: 2026-03-01
  • DOI: https://doi.org/10.1183/13993003.02263-2025
  • OpenAlex record: View
  • Image credit: Photo by Ortopediatri Çocuk Ortopedi Akademisi on Unsplash (SourceLicense)
  • Disclosure: This post is an AI-generated summary of a research work. It was prepared by an editor. The original authors did not write or review this post.